Aaron M Drucker1, Abrar A Qureshi2, Caroline Amand3, Sara Villeneuve4, Abhijit Gadkari5, Jingdong Chao5, Andreas Kuznik5, Gaëlle Bégo-Le-Bagousse3, Laurent Eckert3. 1. Department of Dermatology, Warren Alpert Medical School, Brown University, Providence, RI; Division of Dermatology, Department of Medicine, University of Toronto and Women's College Hospital and Women's College Research Institute, Toronto, Ontario, Canada. Electronic address: aaron_drucker@brown.edu. 2. Department of Dermatology, Warren Alpert Medical School, Brown University, Providence, RI. 3. Sanofi, Chilly-Mazarin, France. 4. VIDATA STATS, Levallois-Perret, France. 5. Regeneron, Tarrytown, NY.
Abstract
BACKGROUND: Data on health care resource utilization (HCRU) and costs for patients with atopic dermatitis (AD) are lacking. OBJECTIVE: The objective of this study was to determine HCRU and costs associated with AD in US adults. METHODS: This retrospective study identified patients with AD from the Truven Health Marketscan Commercial Claims and Encounters database during 2013 based on ≥2 claims with International Classification of Diseases, Ninth Revision code 691.8 (n = 10,533; first claim = index event); 1-year continuous enrollment before and after index was required. Patients were age- and gender-matched in a 1:3 ratio to controls without AD (n = 31,599). Patients with AD were further categorized into 2 groups, with treatment regimens as surrogates for increasing disease severity: claim for phototherapy or systemic immunomodulatory agents (more severe) or no claim for either (less severe). Incremental differences in resource use and costs were evaluated using multivariate analysis. RESULTS: AD was associated with higher utilization and costs across resource categories (all P < .0001); adjusted total incremental annual costs were $3,302. Resource utilization and costs were higher in the more severe group, with adjusted total incremental annual costs of $4,463. CONCLUSION: AD is associated with significant incremental health care utilization and costs, which are higher in patients with more severe disease.
BACKGROUND: Data on health care resource utilization (HCRU) and costs for patients with atopic dermatitis (AD) are lacking. OBJECTIVE: The objective of this study was to determine HCRU and costs associated with AD in US adults. METHODS: This retrospective study identified patients with AD from the Truven Health Marketscan Commercial Claims and Encounters database during 2013 based on ≥2 claims with International Classification of Diseases, Ninth Revision code 691.8 (n = 10,533; first claim = index event); 1-year continuous enrollment before and after index was required. Patients were age- and gender-matched in a 1:3 ratio to controls without AD (n = 31,599). Patients with AD were further categorized into 2 groups, with treatment regimens as surrogates for increasing disease severity: claim for phototherapy or systemic immunomodulatory agents (more severe) or no claim for either (less severe). Incremental differences in resource use and costs were evaluated using multivariate analysis. RESULTS:AD was associated with higher utilization and costs across resource categories (all P < .0001); adjusted total incremental annual costs were $3,302. Resource utilization and costs were higher in the more severe group, with adjusted total incremental annual costs of $4,463. CONCLUSION:AD is associated with significant incremental health care utilization and costs, which are higher in patients with more severe disease.
Authors: Richard D A Hudson; Mahreen Ameen; Susannah M C George; Catherine A Harwood; Richard B Weller; John T Lear; Rajesh Rout; Thishi Surendranathan; Milos Petrovic; Anthony P Bewley Journal: Clinicoecon Outcomes Res Date: 2022-04-04